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Abstract
Background. Intravenous ascorbic acid (IV AA) has been used extensively in cancer patients throughout the United States.
Currently, there are limited data on the safety and clinical effects of IV AA. The purpose of this study was to expand the
current literature using a retrospective analysis of adverse events and symptomatic changes of IV AA in a large sample
of cancer patients. Methods. We conducted a retrospective chart review of all patients receiving IV AA for cancer at the
Thomas Jefferson University Hospital over a 7-year period. We assessed all reports of adverse events, laboratory findings,
and hospital or emergency department admissions. We also reviewed quality-of-life data, including fatigue, nausea, pain,
appetite, and mood. Results. There were 86 patients who received a total of 3034 doses of IV AA ranging from 50 to
150g. In all, 32 patients received only ascorbic acid as part of their cancer management (1197 doses), whereas 54 patients
received ascorbic acid in conjunction with chemotherapy (1837 doses). The most common adverse events related to
ascorbic acid were temporary nausea and discomfort at the injection site. All events reported in the ascorbic acid alone
group were associated with less than 3% of the total number of infusions. Patients, overall, reported improvements in
fatigue, pain, and mood while receiving ascorbic acid. Conclusions. The results of this retrospective analysis support the
growing evidence that IV AA is generally safe and well tolerated in patients with cancer, and may be useful in symptom
management and improving quality of life.
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Introduction
A large number of cancer patients reportedly receive intravenous ascorbic acid (IV AA) with or without concomitant
chemotherapy, often in nonconventional health care settings.1 Although IV AA generally is regarded as safe, there
are limitations to the currently available data. Clinically,
ascorbic acid has been administered intravenously in doses
as high as 200 g/d without adverse consequences.2 We have
previously published initial safety data for doses of 75 and
100 g IV AA in patients with metastatic pancreatic cancer
receiving the combination of gemcitabine, erlotinib, and IV
AA.3 We did not find significant adverse events beyond
what was expected from the chemotherapy alone.
A phase I study at McGill University4 of 24 patients
with terminal cancers reported no toxicity at IV AA doses
of up to 125g. Another study involved 9 patients with
metastatic pancreatic cancer who received gemcitabine,

and IV AA showed no dose-limiting toxicity at similar
doses.5 A more recent phase I-II study by Hoffer et al6
evaluated adverse events in 14 patients with advanced
cancers receiving high-dose IV AA in combination with
cytotoxic chemotherapy. The authors reported that the IV
AA was overall safe and well tolerated, though some
patients had transient adverse events such as nausea or
vomiting during or shortly after IV AA infusions.
Because ascorbic acid is broken down to oxalic acid,
there has been concern that high-dose IV AA could
potentially cause oxalate kidney stones, especially in patients
1
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with preexisting renal dysfunction. Renal dysfunction would
lead to longer dwell time of ascorbate in the high pH environment of the renal extracellular fluid and urinary space
with consequent calcium oxalate precipitation. A large epidemiological study of 48 850 men by Thomas et al7 showed
that individuals taking oral ascorbic acid were at an increased
risk for developing kidney stones and that the incidence
increased in men taking the highest doses. The most recent
large epidemiological study based on the Health Professionals
Follow-up Study has similarly shown that higher daily vitamin C intake is associated with an increased risk of developing kidney stones in men, but not in women.8 There have
been several case reports of renal failure associated with
oxalate crystal formation in patients with preexisting kidney
disorders who received high doses of oral vitamin C9 and IV
vitamin C.10,11 It is not determined if these data indicate an
increased risk of developing kidney stones in patients with
normal renal function receiving intermittent high IV doses.
However, it is essential to measure creatinine in patients
prior to receiving IV AA and to intermittently monitor kidney function throughout the time period while receiving
infusions to ensure that kidney function is not affected.
A few reports and reviews suggest that IV AA might
improve clinical symptoms such as fatigue or nausea associated with either the cancer itself or resulting from the
effects of chemotherapy medications.12-14 A phase I study
showed improvements in global, physical, emotional, and
social well-being as well as reduction in fatigue, nausea,
pain, dyspnea, and insomnia.15 However, these measures
were not evaluated for statistical significance.
Overall, the available data suggest that serious adverse
events related to high-dose IV AA are uncommon, though
caution is warranted in patient subgroups, such as those
with renal disease. The phase I and safety studies to date
have either focused on a particular patient group and/or
have very small numbers. This article provides the first
analysis of safety data for IV AA in a large, heterogeneous
population of cancer patients in a setting that may be more
representative of common clinical practice. We also provide
a secondary analysis of impact on clinical symptoms. Our
goal in presenting these data is to provide additional information on safety of current practices and to inform next
steps of clinical investigation.

Methods
This retrospective study was approved by the Thomas
Jefferson University Institutional Review Board (IRB No.
13D.154, originally approved on April 1, 2013) as a retrospective evaluation of existing clinical data and was conducted according to the principles expressed in the
Declaration of Helsinki.
This was a retrospective study covering a 7-year period
from 2007 to 2014 of all cancer patients presenting to the

913
Marcus Institute of Integrative Health, Thomas Jefferson
University, who received treatment with IV AA. Patients
included had a diagnosis of cancer and had received at least
5 doses of IV AA. We established a minimum of 5 doses to
ensure sufficient use of the IV AA to evaluate directly
related effects. The dosage range was 50 to 150 g. For all
patients, the ascorbic acid was mixed in a 1-L bag of 5%
dextrose in water with enough fluid removed in order to
mix in the ascorbic acid along with magnesium chloride and
calcium gluconate. The IV AA was infused over 2 to 3 hours
as tolerated by the patient. The dose was determined by the
clinical judgment of the treating physician.
All patients had a normal glucose-6-phosphate dehydrogenase (G6PD) level prior to initiating the IV AA. It is
the Marcus Institute clinical policy to check the G6PD
enzyme level because of its role in the production of
reduced nicotinamide adenine dinucleotide phosphate in
the hexose-monophosphate shunt16 and subsequently in
the generation of reduced glutathione in the red cell for
protection against oxidative stress. Because high doses of
IV AA result in the production of hydrogen peroxide,
those individuals without the G6PD enzyme will experience significant hemolysis of the red blood cells.17 All
patients had kidney function checked prior to initiating IV
AA. The clinic policy requires all patients to have a normal creatinine level and monitored creatinine levels at
regular intervals depending on the frequency of infusions.
The clinic guidelines also exclude patients with a history
of recurrent kidney stones.
The standard IV AA infusion was performed using the
following general procedures. When patients arrived, their
blood pressure, heart rate, respiratory rate, and temperature
were obtained at baseline. The IV was started either peripherally or through an indwelling port. Infusions were prepared with the prescribed dose of IV AA mixed with
approximately 1 g of magnesium chloride and 1 g of calcium gluconate. The infusion was run in over 2 to 3 hours.
The speed of the infusion was adjusted to tolerance by the
patient because the large hyperosmolar load can result in
symptoms such as thirst, polyuria, and abdominal or chest
discomfort. When patients experienced symptoms such as
these or nausea or lightheadedness, the infusion rate was
slowed until the symptoms improved. If the symptoms
improved, the infusion proceeded at a lower rate. If the
symptoms did not improve, that particular infusion was
stopped, and the patient was evaluated prior to restarting
future infusions. Vital signs were monitored throughout the
infusion period and then once more after the infusion was
completed and the IV removed. The patients were assessed
for any adverse effects and then discharged.
Data were obtained through a thorough chart review,
including physician and nursing notes, laboratory values
(complete metabolic profile, complete blood count, and
liver function tests when available), imaging studies,
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Table 1. Types of Cancer in Patients Receiving High-Dose IV
AA.

Cancer Type
Bladder
Breast
Colon
Endometrial
Ewing’s
Chronic lymphocytic
leukemia
Hepatocellular
carcinoma
Lung
Lymphoma
Mesothelioma
Ovarian
Pancreatic
Penile
Prostate
Total

Patients With
IV AA
Alone (n)

Patients With
IV AA Plus
Chemotherapy (n)

1
4
5
2
0
1

0
6
3
0
1
1

4

1

2
2
1
1
1
1
4
32

5
1
1
3
29
0
1
54

Abbreviations: IV AA, intravenous ascorbic acid.

emergency room visits, and hospital admissions during the
treatment period. Adverse events were evaluated by standard National Cancer Institute clinical criteria 4.0.18

Analyses
The number of adverse events in the patients receiving IV
AA alone compared with those receiving ascorbic acid in
combination with chemotherapy was compared using a
Fisher exact test. We also performed a qualitative assessment of clinical symptoms such as fatigue, mood, or appetite, which were evaluated based on patient reports described
in the clinical charts. Patients are routinely asked at each
visit for any changes in their symptoms. For each symptom
reported initially (ie, prior to starting IV AA), we evaluated
whether patients reported improved, stable, or worsening of
that symptom. We included only symptoms that were initially reported by patients; so if a person had no nausea to
begin with and did not develop any, then that symptom is
not included in the table. Any symptoms that arose during
treatment were considered to represent worsening (ie, the
new onset of edema). For mood, we utilized clinical report
data routinely collected as part of the Marcus Institute clinical procedures, including the subjective report of mood,
depressed feelings, anxiety, major stressors, or other psychosocial issues. Patients who develop symptoms are routinely asked whether their symptoms were improved, stable,
or worse compared with the prior visit. Appetite/weight loss
was reported and measured in all patients. If there was no

change in reported appetite and if the weight was within 5%
during the period that the patient was receiving IV AA, it
was regarded as stable. Weight gain and appetite improvement are reported as “improved,” whereas the new onset of
weight loss or loss of appetite are reported as “worsening”
(no patients were found who were purposely trying to lose
weight during their treatment period). In addition, the number of patients reporting improved or stable symptoms in
each symptom category was compared with the number of
patients reporting worsening symptoms using the Fisher
exact test.

Results
Overall, 86 cancer patients were treated between 2007 and
2014, with a total of 3083 doses of IV AA given (median
number of doses per patient was 27). There were 56 women
and 30 men with a median age of 60 years (range 19-87).
This was a heterogeneous patient group in terms of cancer
diagnosis and staging. The cancer types for the entire cohort
are shown in Table 1. A total of 54 patients received the IV
AA in combination with chemotherapy (which included
drugs such as paclitaxel, carboplatin, sorafenib, irinotecan,
and gemcitabine). The other 32 patients only received the
ascorbic acid. There were no significant differences in cancer types, although all the pancreatic cancer patients but one
received chemotherapy.
Adverse events for the entire group, divided into those
receiving ascorbic acid alone and also in combination with
chemotherapy, are provided in Table 2. The table reveals
adverse events common in those patients receiving chemotherapy such as reductions in platelets and hemoglobin.
These adverse events are known to be associated with the
chemotherapy regimens received. Only 2 patients receiving
IV AA alone had mild reductions in hemoglobin levels, and
both had a history of anemia prior to receiving the infusions. Furthermore, their low hemoglobin levels improved
without transfusions and while still receiving IV AA.
The most common adverse events were nausea and vomiting, headache, and discomfort at the injection site. Most of
these symptoms were self-limited to the time of individual
infusions. For all patients, adverse events were reported in
less than 5% of all infusions. In patients receiving only the
IV AA, adverse events were reported in less than 3% of all
infusions.
Patients with underlying diabetes did not have additional
adverse effects, but administration of the ascorbic acid is
known to falsely elevate glucometer readings,19,20 and this
was observed in 3 patients. One potentially problematic
issue, observed in 5 patients (3 in conjunction with chemotherapy and 2 with IV AA alone), was worsening of baseline
ascites or edema. With regard to laboratory assessments that
were available on 71 patients, there were no significant
changes in electrolytes, blood urea nitrogen, creatinine, or
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Table 2. Adverse Event Chart for Patients Divided Into Those Receiving Chemotherapy and Those Not Receiving Chemotherapy
(Based on Standard NCI Criteria).
Adverse Event
Pain at injection site
Grade 1
Headache
Grade 1
Cold/Chills
Grade 1
Allergic reaction
Grade 1
Grade 3
Platelet count decreased
Grade 1
Grade 2
Grade 3
Anemia
Grade 2
Grade 3
Neutrophil count decreased
Grade 2
Grade 3
Hyponatremia
Grade 3
Hypokalemia
Grade 4
Elevated glucose
Grade 2
Blood pressure
Hypotension (grade 3)
Hypertension (grade 2, found on
monitoring but without clinical
symptoms)
Renal failure
Grade 2
Grade 3
Renal colic
Grade 1 (kidney stone)
Ascites
Grade 2
Gastrointestinal
Nausea/Vomiting
  (Grade 1)
  (Grade 3)
Biliary obstruction
  (Grade 2)
  (Grade 3)
Obstruction/Ileus (grade 3)
Gastric hemorrhage
  (Grade 2)
Colonic hemorrhage
  (Grade 3)
   Ascites (grade 2)

IV AA + Chemotherapy, Number
of Events (n = 54, 1837 doses)

IV AA Alone, Number of
Events (n = 32, 1197 doses)

7

8

6

4

4

1

2
0

0
2

9
6
2

0
0
0

12
3

1
1

1
5

0
0

0

1

1

0

3

0

2
5

1
4

1
0

0
1

0

1

3

2

15
2

6
0

1
3
1

0
0
0

1

0

1
1

0
0
(continued)
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Table 2. (continued)
Adverse Event

IV AA + Chemotherapy, Number
of Events (n = 54, 1837 doses)

Infection
Conjunctival (grade 2)
Urinary tract infection (grade 3)
Pneumonia (grade 3)
Thromboembolic event
Grade 3
Grade 4
Myocardial infarction
Grade 4
Total

IV AA Alone, Number of
Events (n = 32, 1197 doses)

1
2
2

0
1
1

2
3

0
0

2
109

0
35

Abbreviations: IV AA, intravenous ascorbic acid; NCI, National Cancer Institute.

liver function tests when the entire cohort of patients was
evaluated as a whole or divided into ascorbic acid alone or in
combination with chemotherapy. Decreases in total blood
cell counts were observed in patients receiving chemotherapy but generally not in those receiving ascorbic acid alone.
No serious adverse events were observed in blood cell counts.
One potential concern with IV AA is the formation of
oxalate crystals in the urine, which could lead to kidney
stones or even oxalate nephropathy.10,11 In our cohort, there
was 1 patient who developed an elevated creatinine while
receiving ascorbic acid, but the workup, including urinalysis and imaging, suggested that the worsening kidney function was related to recurrent infections and progressive
lymphoma resulting in obstruction. No crystals were
detected in the urine, and ascorbic acid was continued during this time as determined by the medical oncology team,
urologist, and patient because there were no other alternative treatments available. Another patient presented to the
hospital with nausea and vomiting and was found to have an
elevated creatinine, which normalized in 2 days after medical management that included IV hydration. A third patient
was reported to have developed a kidney stone while on IV
AA, but this was not associated with any renal problems.
The results with regard to symptomatic response are provided in Table 3. For all patients receiving IV AA, there was
a significant improvement or stability in fatigue, bowel habits, and pain symptoms (P < .05). A small number of patients
with mood disturbances, such as depression, also generally
reported improvements in their overall mood. Appetite and
weight loss was improved in 15 patients and was not substantially altered in 70 patients. There were only 2 reports in
which appetite was worsened or weight loss accelerated in
the entire group.

Discussion
IV AA as cancer therapy was largely discarded several
decades ago when 2 randomized trials of oral vitamin C

therapy failed to demonstrate therapeutic benefit.21,22
However, more recent pharmacokinetic modeling indicates
that IV administration of ascorbic acid produces a 25-fold
or greater plasma concentration than the same dose given
orally.23 Chen et al24 have reported that ascorbic acid levels
achievable in vivo only by IV infusion are selectively cytotoxic in vitro to various cancer cell lines but not to normal
cells by a mechanism involving formation of hydrogen peroxide. This action of IV AA is consistent with a growing
literature that reactive oxygen species play an important
role in the mechanism of action of proven cancer treatments
and that impaired oxygen-reduction balance in cancer cells
might cause induced reactive oxygen species to selectively
kill cancer cells.25,26 We recently confirmed this previous
work with a series of cell line experiments and also observed
that ascorbate deregulates cellular calcium homeostasis,
thereby promoting cell death.27 There are also other proposed mechanisms of action. Ascorbate functions as a
cofactor for a group of enzymes (Fe and 2-oxoglutaratedependent dioxygenases) such as hypoxia inducible factor
(HIF) hydroxylases, which affect HIF protein levels through
marking HIF for proteosomal degradation and also cotranscription factor binding. High levels of ascorbate result in
lower expression of HIF, which decreases tumor growth
and increases sensitivity of cancer cells to the toxic effects
of vitamin C.28 Ascorbate also increases the ten-eleven translocation enzyme activity associated with DNA demethylation, hence regulating gene transcription associated with
cancer formation.29 Thus, it is possible that this mechanism
represents an additional role for ascorbate in modulating
genome activity that could affect tumor cells and growth.
Several small studies, including a phase I study by our
group, have reported on the initial safety and effectiveness
of IV AA, given either alone or with other agents.3,4,6 Overall,
these studies have suggested that high-dose IV AA is relatively safe and well tolerated, with or without concomitant
chemotherapy. In this article we reported on a clinical experience of administering IV AA that may be reflective of a
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Table 3. Number of Patients Reporting Improvement, Stability, or Worsening of Specific Symptoms (n = 86 Total Cancer Patients).
Change in
Symptoms

Fatigue

Diarrhea/
Constipation

Worse
5
2
Stable
15
5
Improved
20
6
n = 54 Cancer patients receiving chemotherapy (1837 doses)
Worse
4
2
Stable
10
3
Improved
10
6
n = 32 Cancer patients without chemotherapy (1197 doses)
Worse
1
0
Stable
5
2
Improved
10
0

more typical environment and patient population for this
treatment versus a more controlled research environment.
For this reason, we retrospectively evaluated all patients
with cancer treated with IV AA at the Marcus Institute over
a 7-year period. The results of the present analysis are based
on 86 patients who received IV AA in doses between 50 and
150 g. The total number of doses received was 3034.
In regard to adverse events, IV AA was generally well
tolerated, with only 3% to 5% of all infusions associated
with an adverse event. The most common adverse event
was nausea and vomiting which was self-limited during
infusions and resolved quickly afterward. Although the
mechanism of these symptoms is not known, the anecdotal
clinical experience has been that eating lightly helps mitigate them. Another common adverse effect was pain or discomfort at the injection site. Common clinical practices to
mitigate this issue is slowing the infusion rate. In patients
expected to receive a substantial number of IV AA doses,
consideration of a port-a-cath or permanent line is warranted. Patients in the group receiving chemotherapy plus
IV AA were found to have reductions in their blood counts
consistent with the effect of chemotherapy. There was no
evidence that IV AA alone had an impact on measured
blood counts.
The 2 most potentially problematic adverse events relate
to fluid collection and renal function. We had 5 patients
with existing ascites or edema who experienced worsening
of this symptom. Whereas the worsening may have simply
been related to the progression of their disease, third spacing is a clinical condition that should be watched carefully
in patients receiving IV AA, which is a hypertonic solution
typically given in a large quantity of fluid (ie, 750-1000
mL). On the other hand, a report by Hoffer et al4 described
a case in which IV AA substantially reduced a patient’s
ascites by acting as an osmotic diuretic, and Ma et al30 also
indicated a reduction in ascites with vitamin C in combination with chemotherapy in ovarian cancer. Given that our

Pain

Appetite/
Weight Loss

Ascites/
Edema

Mood

4
9
11

2
69
15

4
1
0

0
1
6

3
7
10

1
44
9

3
1
0

0
1
4

1
2
1

1
25
6

1
0
0

0
0
2

patients had worsening ascites and edema, future studies
will have to better assess the impact of IV AA on patients
with substantial third spacing of fluids.
Particular care should be taken when patients have
preexisting impairment in renal function, which would
make them unable to clear a hypertonic fluid load.
Although this was not the case in our cohort, care should
be taken when treating patients with known third spacing, particularly if it is associated with lymphadenopathy
that impairs venous return from the legs or is associated
with a pericardial effusion. Additionally, given the potential for an osmotic diuresis, we noted that 2 patients had
electrolyte abnormalities: one with hyponatremia and
one with hypokalemia. Given the potential effect of IV
AA on electrolytes, it is important to evaluate electrolytes at regular intervals, particularly in those patients
with a history of impaired renal function, patients on
diuretics or other medications that might affect electrolytes, and patients with a known history of electrolyte
disturbances.
It is known that ascorbic acid increases urine oxalate,
which suggests a potential risk for developing kidney
stones.31 Furthermore, several studies have demonstrated
an increased risk of kidney stone formation with oral supplementation, particularly in men. However, other studies
have suggested that high doses of AA may even be protective.32 Pharmacokinetic studies have also explored
whether high doses of vitamin C might increase the risk
of forming kidney stones. For example, one study of 16
patients with advanced cancer found that when studied
using correct procedures for handling, storing, and analyzing the urine, less than 0.5% of a large IV dose of
ascorbic acid in people with normal renal function was
found as oxalic acid.33
In the medical literature, several cases of acute oxalate
nephropathy were reported in patients with preexisting
renal insufficiency given large IV doses of vitamin C.9,10,11
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In our evaluation, we found 2 patients with increased creatinine, and both cases were explained by causes other than
ascorbic acid effects. We also had 1 patient who reported
developing a kidney stone while receiving IV AA. The type
of stone could not be ascertained, and thus, it is possible that
the IV AA contributed to the formation of the kidney stone
in this patient. However, it should be noted that the overall
prevalence of kidney stones in the general population is 1%
to 2%.34 Nonetheless, patients should be monitored regularly for the possibility of developing renal impairment or
kidney stones during the course of receiving IV AA.
It is noted that care must be taken in patients with diabetes because AA can falsely elevate glucometer readings substantially (ie, values can range greater than 400 mg/dL).35
Pharmacokinetic studies have generally observed an elimination half-life of approximately 2 hours,15,36 with the implication that glucometer readings could remain abnormal for 6
to 8 hours postinfusion. Thus, it is important to remind
patients with diabetes to be cautious with regard to treating
themselves with added insulin if readings remain elevated
after receiving IV AA. Patients should typically wait until
the following morning (ie, at least 6-8 hours) to recheck their
glucose levels when the AA has been substantially eliminated, so as not to interfere with glucose measurement.
The adverse events analysis of this retrospective study
will hopefully add more safety data regarding the use of IV
AA in patients with cancer. The comparison of patients
receiving IV AA with and without concomitant chemotherapy also helps demonstrate which adverse events are more
specifically attributable to the ascorbic acid rather than the
chemotherapy. As expected, there were fewer toxicities in
the group that received IV AA alone. It is not known if the
group receiving both had fewer toxicities from the addition
of IV AA, though a study by Ma et al30 of 25 ovarian cancer
patients showed that those treated with IV AA along with
carboplatin and paclitaxel had fewer grade 1 and 2 adverse
events compared with those treated with the chemotherapy
agents alone.
In terms of symptoms, this heterogeneous patient cohort,
receiving IV AA alone or in combination with chemotherapy, qualitatively described improvements in energy, nausea, pain, and mood. These are common symptoms in
cancer patients and have been a target for studies on the
potential beneficial effect of ascorbic acid. For example,
one prospective study of 60 patients with advanced cancer
found that IV AA (25-100 g/session) administered twice a
week resulted in statistically significant decreases in fatigue,
insomnia, and constipation after 2 weeks, based on the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30),
and a reduction in pain after 4 weeks.37 It also should be
noted that fatigue worsened in 5 patients after stopping
ascorbic acid (3 were in the chemotherapy group and 2 were
in the nonchemotherapy group). A systematic review of

Integrative Cancer Therapies 17(3)
quality-of-life studies using vitamin C also showed some
evidence for beneficial effect.13 These studies and the findings from the present retrospective analysis all have limitations that make it impossible to draw conclusions regarding
effects on clinical symptoms. In addition, the Mg included
in our infusions has also been suggested to improve mood
in patients, although a recent randomized crossover trial of
4 g Mg (whereas our infusions typically have 1 g Mg) did
not find any benefit in patients with treatment-resistant
depression.38 Future prospective studies that are randomized and controlled with strong statistical analyses will be
necessary to better assess any potential benefits of IV AA in
cancer patients.
Limitations for this retrospective analysis include inherent problems reviewing past clinical charts, which restricts
the analysis to data that are available in those charts. Doses
were determined based on the clinical decision of the treating physician, but future approaches to determining ways of
standardizing the doses will be important for both research
and clinical applications. As mentioned, complete laboratory data were not available on 16 patients, but there was no
clinical evidence that these patients experienced untoward
medical events that might have been related to laboratory
abnormalities. Symptomatic reporting is also limited to
what was reported by the patient and the physician. Because
the patients were seen clinically, it was important to assess
for adverse events, so it is unlikely that there is an underreporting of negative effects of the IV AA. However, it is certainly possible that symptomatic changes, for better or
worse, were not included in the charts, thus preventing any
firm conclusions. Furthermore, we might expect reporting
bias in patients receiving the IV AA, and therefore, future
studies should utilize more formal questionnaires and scales
for the evaluation of subjective symptoms such as fatigue,
mood, and pain. In addition, because this was a retrospective evaluation, there was no control group (ie, a placebo IV
with just saline), which might have yielded similar symptomatic changes. However, the ability to compare patients
receiving IV AA with and without chemotherapy provides
some knowledge as to which adverse events are more specific to the IV AA.
The results, and limitations, that arise from this retrospective analysis suggest the need for larger-scale randomized controlled trials to determine the ability of IV AA to
improve the quality of life in cancer patients, especially
those receiving chemotherapy.

Conclusion
In this systematic retrospective evaluation of 86 patients
with cancer who were given a total of 3034 doses of IV AA,
the treatment was found to be generally well tolerated and
safe, with few adverse events reported. Also observed were
subjective improvements in symptoms such as fatigue,
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pain, and mood. Future studies should more specifically
evaluate the mitigating effect of IV AA on adverse events
related to chemotherapy and improvements in valid qualityof-life measures as well as the potential effectiveness in the
management of different types of cancer.
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